Crise blástica

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: chronic myeloid leukemia [internet publication].Texto completo

Smith G, Apperley J, Milojkovic D, et al; British Society for Haematology. A British Society for Haematology guideline on the diagnosis and management of chronic myeloid leukaemia. Br J Haematol. 2020 Oct;191(2):171-93.Texto completo  Resumo

Hochhaus A, Saussele S, Rosti G, et al; ESMO Guidelines Committee. Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul 1;28(suppl 4):iv41-51.Texto completo  Resumo

Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020 Apr;34(4):966-84.Texto completo  Resumo

1. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022 Jul;36(7):1703-19.Texto completo  Resumo

2. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: chronic myeloid leukemia [internet publication].Texto completo

3. Smith G, Apperley J, Milojkovic D, et al; British Society for Haematology. A British Society for Haematology guideline on the diagnosis and management of chronic myeloid leukaemia. Br J Haematol. 2020 Oct;191(2):171-93.Texto completo  Resumo

4. Ch'ang HJ, Tien HF, Wang CH, et al. Comparison of clinical and biologic features between myeloid and lymphoid transformation of Philadelphia chromosome positive chronic myeloid leukemia. Cancer Genet Cytogenet. 1993 Nov;71(1):87-93. Resumo

5. Hehlmann R, Hochhaus A, Baccarani M, et al. Chronic myeloid leukaemia. Lancet. 2007 Jul 28;370(9584):342-50. Resumo

6. Ali E, Soliman A, De Sanctis V, et al. Priapism in patients with chronic myeloid leukemia (CML): a systematic review. Acta Biomed. 2021 Jul 1;92(3):e2021193.Texto completo  Resumo

7. Emerson G, Kaide CG. Rapid fire: acute blast crisis/hyperviscosity syndrome. Emerg Med Clin North Am. 2018 Aug;36(3):603-8. Resumo

8. Kirwin M, Yee J. Blast crisis. J Educ Teach Emerg Med. 2020 Apr;5(2):S55-77.Texto completo  Resumo

9. Stone MJ, Bogen SA. Evidence-based focused review of management of hyperviscosity syndrome. Blood. 2012 Mar 8;119(10):2205-8.Texto completo  Resumo

10. Brioli A, Lomaia E, Fabisch C, et al. Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry. Leukemia. 2024 May;38(5):1072-1080.Texto completo  Resumo

11. Jain P, Kantarjian HM, Ghorab A, et al. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: cohort study of 477 patients. Cancer. 2017 Nov 15;123(22):4391-402.Texto completo  Resumo

12. Cortes JE, Talpaz M, Kantarjian H. Chronic myelogenous leukemia: a review. Am J Med. 1996 May;100(5):555-70. Resumo

13. Hoffmann VS, Baccarani M, Hasford J, et al. Treatment and outcome of 2904 CML patients from the EUTOS population-based registry. Leukemia. 2017 Mar;31(3):593-601. Resumo

14. Hehlmann R, Lauseker M, Saußele S, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017 Nov;31(11):2398-2406.Texto completo  Resumo

15. National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts: leukemia - chronic myeloid leukemia (CML). 2024 [internet publication].Texto completo

16. Malhotra H, Radich J, Garcia-Gonzalez P. Meeting the needs of CML patients in resource-poor countries. Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):433-42.Texto completo  Resumo

17. Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood. 1994 Dec 15;84(12):4064-77.Texto completo  Resumo

18. Schubauer-Berigan MK, Daniels RD, Fleming DA, et al. Risk of chronic myeloid and acute leukemia mortality after exposure to ionizing radiation among workers at four US nuclear weapons facilities and a nuclear naval shipyard. Radiat Res. 2007 Feb;167(2):222-32. Resumo

19. Leuraud K, Richardson DB, Cardis E, et al. Ionising radiation and risk of death from leukaemia and lymphoma in radiation-monitored workers (INWORKS): an international cohort study. Lancet Haematol. 2015 Jul;2(7):e276-81.Texto completo  Resumo

20. Wang L, Li L, Chen R, et al. Understanding and monitoring chronic myeloid leukemia blast crisis: how to better manage patients. Cancer Manag Res. 2021;13:4987-5000.Texto completo  Resumo

21. Senapati J, Jabbour E, Kantarjian H, et al. Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia. Leukemia. 2023 Jan;37(1):5-17. Resumo

22. Bavaro L, Martelli M, Cavo M, et al. Mechanisms of disease progression and resistance to tyrosine kinase inhibitor therapy in chronic myeloid leukemia: an update. Int J Mol Sci. 2019 Dec 5;20(24):6141.Texto completo  Resumo

23. Branford S, Wang P, Yeung DT, et al. Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. Blood. 2018 Aug 30;132(9):948-961.Texto completo  Resumo

24. Wang W, Cortes JE, Tang G, et al. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood. 2016 Jun 2;127(22):2742-50.Texto completo  Resumo

25. Ali Hailan YM, Al-Dubai HN, Yassin MA. Chronic myeloid leukemia following exposure to radioactive iodine (I131): a systematic review. Oncology. 2023;101(6):362-8.Texto completo  Resumo

26. Ural AU, Beyzadeoglu M, Avcu F, et al. Chronic myeloid leukemia following radiotherapy for carcinoma of the cervix: report of a case and brief review of the literature. Am J Hematol. 2007 May;82(5):415-6.Texto completo  Resumo

27. Miyoshi I, Mori M, Yamasaki I, et al. Is there an entity of radiation-induced chronic myeloid leukemia? Report of a aase and brief review of the literature. J Clin Exp Hematop. 2020;60(1):24-5.Texto completo  Resumo

28. Tsushima H, Iwanaga M, Miyazaki Y. Late effect of atomic bomb radiation on myeloid disorders: leukemia and myelodysplastic syndromes. Int J Hematol. 2012 Mar;95(3):232-8. Resumo

29. Cortes JE, Talpaz M, O'Brien S, et al. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. Cancer. 2006 Mar 15;106(6):1306-15.Texto completo  Resumo

30. Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 Sep 15;140(11):1200-28.Texto completo  Resumo

31. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013 Aug 8;122(6):872-84.Texto completo  Resumo

32. Cross NCP, Ernst T, Branford S, et al. European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia. Leukemia. 2023 Nov;37(11):2150-167.Texto completo  Resumo

33. Müller MC, Cross NC, Erben P, et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia. 2009 Nov;23(11):1957-63. Resumo

34. Atteya A, Ahmad A, Daghstani D, et al. Evaluation of hepatitis B reactivation among patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer Control. 2020 Jan-Dec;27(1):1073274820976594.Texto completo  Resumo

35. Hochhaus A, Saussele S, Rosti G, et al; ESMO Guidelines Committee. Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul 1;28(suppl 4):iv41-51.Texto completo  Resumo

36. Rodgers R, Latif Z, Copland M. How I manage priapism in chronic myeloid leukaemia patients. Br J Haematol. 2012 Jul;158(2):155-64. Resumo

37. Soupir CP, Vergilio JA, Dal Cin P, et al. Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis. Am J Clin Pathol. 2007 Apr;127(4):642-50. Resumo

38. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring. Am J Hematol. 2024 Nov;99(11):2191-212.Texto completo  Resumo

39. Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020 Apr;34(4):966-84.Texto completo  Resumo

40. Deau B, Nicolini FE, Guilhot J, et al. The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study). Leuk Res. 2011 Jun;35(6):777-82. Resumo

41. Copland M, Slade D, McIlroy G, et al. Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial. Lancet Haematol. 2022 Feb;9(2):e121-32.Texto completo  Resumo

42. Copland M. Treatment of blast phase chronic myeloid leukaemia: a rare and challenging entity. Br J Haematol. 2022 Dec;199(5):665-78.Texto completo  Resumo

43. Abaza Y, Kantarjian H, Alwash Y, et al. Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. Am J Hematol. 2020 Nov;95(11):1288-95.Texto completo  Resumo

44. Ruggiu M, Oberkampf F, Ghez D, et al. Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia. Leuk Lymphoma. 2018 Jul;59(7):1659-65.Texto completo  Resumo

45. DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020 Aug 13;383(7):617-29.Texto completo  Resumo

46. Osman AEG, Deininger MW. Chronic myeloid leukemia: modern therapies, current challenges and future directions. Blood Rev. 2021 Sep;49:100825. Resumo

47. Chalandon Y, Thomas X, Hayette S, et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood. 2015 Jun 11;125(24):3711-9.Texto completo  Resumo

48. Strati P, Kantarjian H, Thomas D, et al. HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. Cancer. 2014 Feb 1;120(3):373-80.Texto completo  Resumo

49. Morita K, Kantarjian HM, Sasaki K, et al. Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib. Cancer. 2021 Aug 1;127(15):2641-7.Texto completo  Resumo

50. Rea D, Legros L, Raffoux E, et al. High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia. Leukemia. 2006 Mar;20(3):400-3. Resumo

51. Deak D, Gorcea-Andronic N, Sas V, et al. A narrative review of central nervous system involvement in acute leukemias. Ann Transl Med. 2021 Jan;9(1):68.Texto completo  Resumo

52. Porkka K, Koskenvesa P, Lundán T, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood. 2008 Aug 15;112(4):1005-12.Texto completo  Resumo

53. Saglio G, Hochhaus A, Goh YT, et al. Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. Cancer. 2010 Aug 15;116(16):3852-61.Texto completo  Resumo

54. Giles FJ, Kantarjian HM, le Coutre PD, et al. Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia. 2012 May;26(5):959-62. Resumo

55. Gambacorti-Passerini C, Kantarjian HM, Kim DW, et al. Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. Am J Hematol. 2015 Sep;90(9):755-68.Texto completo  Resumo

56. Cortes JE, Kim DW, Pinilla-Ibarz J, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018 Jul 26;132(4):393-404.Texto completo  Resumo

57. Saussele S, Haverkamp W, Lang F, et al. Ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute leukemia: recommendations of a German Expert Consensus Panel with focus on cardiovascular management. Acta Haematol. 2020;143(3):217-31.Texto completo  Resumo

58. Müller MC, Cervantes F, Hjorth-Hansen H, et al. Ponatinib in chronic myeloid leukemia (CML): consensus on patient treatment and management from a European expert panel. Crit Rev Oncol Hematol. 2017 Dec;120:52-9.Texto completo  Resumo

59. Shamroe CL, Comeau JM. Ponatinib: a new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Ann Pharmacother. 2013 Nov;47(11):1540-6. Resumo

60. Medicines and Healthcare products Regulatory Agency. Ponatinib (Iclusig): reports of posterior reversible encephalopathy syndrome. Oct 2018 [internet publication].Texto completo

61. Oehler VG, Gooley T, Snyder DS, et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood. 2007 Feb 15;109(4):1782-9.Texto completo  Resumo

62. Boehm A, Walcherberger B, Sperr WR, et al. Improved outcome in patients with chronic myelogenous leukemia after allogeneic hematopoietic stem cell transplantation over the past 25 years: a single-center experience. Biol Blood Marrow Transplant. 2011 Jan;17(1):133-40.Texto completo  Resumo

63. Khoury HJ, Kukreja M, Goldman JM, et al. Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis. Bone Marrow Transplant. 2012 Jun;47(6):810-6.Texto completo  Resumo

64. Carpenter PA, Snyder DS, Flowers ME, et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood. 2007 Apr 1;109(7):2791-3.Texto completo  Resumo

65. Olavarria E, Siddique S, Griffiths MJ, et al. Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood. 2007 Dec 15;110(13):4614-7.Texto completo  Resumo

66. DeFilipp Z, Langston AA, Chen Z, et al. Does post-transplant maintenance therapy with tyrosine kinase inhibitors improve outcomes of patients with high-risk Philadelphia chromosome-positive leukemia? Clin Lymphoma Myeloma Leuk. 2016 Aug;16(8):466-71.e1. Resumo

67. Savani BN, Montero A, Kurlander R, et al. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant. 2005 Dec;36(11):1009-15. Resumo

68. Lübking A, Dreimane A, Sandin F, et al. Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry. Bone Marrow Transplant. 2019 Nov;54(11):1764-74. Resumo

69. Shimada H, Tanizawa A, Kondo T, et al. Prognostic factors for outcomes of allogeneic HSCT for children and adolescents/young adults with CML in the TKI era. Transplant Cell Ther. 2022 Jul;28(7):376-89.Texto completo  Resumo

70. Niederwieser C, Morozova E, Zubarovskaya L, et al. Risk factors for outcome after allogeneic stem cell transplantation in patients with advanced phase CML. Bone Marrow Transplant. 2021 Nov;56(11):2834-41.Texto completo  Resumo

71. Chang YJ, Wu DP, Lai YR, et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: a multicenter, open-label, randomized controlled study. J Clin Oncol. 2020 Oct 10;38(29):3367-76.Texto completo  Resumo

72. Kurbegov D, Giralt S. Chapter 9. Allogeneic transplantation. In: Kantarjian HM, Wolff RA, Koller CA, eds. MD Anderson manual of medical oncology. New York, NY: McGraw-Hill; 2006:197-218.

73. Taplitz RA, Kennedy EB, Flowers CR. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update summary. J Oncol Pract. 2018 Nov;14(11):692-5.Texto completo  Resumo

74. Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America clinical practice guideline update. J Clin Oncol. 2018 May 10;36(14):1443-53.Texto completo  Resumo

75. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: hematopoietic cell transplantation [internet publication].Texto completo

76. Chao N. How I treat sinusoidal obstruction syndrome. Blood. 2014 Jun 26;123(26):4023-6.Texto completo  Resumo

77. Haguet H, Douxfils J, Mullier F, et al. Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis. Expert Opin Drug Saf. 2017 Jan;16(1):5-12. Resumo

78. Abruzzese E, Trawinska MM, de Fabritiis P, et al. Management of pregnant chronic myeloid leukemia patients. Expert Rev Hematol. 2016 Aug;9(8):781-91. Resumo